Brief: Appili Therapeutics Announces Additional Funding For Its ATI-1701 Biodefense Program
27/10/2020 12:47
Oct 27 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS INC - APPILI THERAPEUTICS ANNOUNCES
ADDITIONAL FUNDING FOR ITS ATI-1701 BIODEFENSE PROGRAM
* APPILI THERAPEUTICS INC - U.S. DEPARTMENT OF DEFENSE
AWARDED
OLOGY BIOSERVICES $6.3 MILLION USD FOR ATI-1701 MANUFACTURING
AND DEVELOPMENT WORK
* APPILI THERAPEUTICS INC - DTRA-FUNDED MANUFACTURING WORK
WILL BE
USED TO PROVIDE VACCINE SUPPLY FOR FUTURE DEVELOPMENT OF
APPILI'S ATI-1701 PROGRAM
Source text for Eikon: ID:nBw3W12zma
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez